Clinical Trials List
2011-10-01 - 2025-06-30
Phase III
Terminated7
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Yi-Fang Tsai Division of General Surgery
- 金光亮 Division of General Surgery
- Chun-Yu Liu Division of Hematology & Oncology
- 邱仁輝 Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Yao-Lung Kuo Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 林璟宏 Division of Hematology & Oncology
- 郭文宏 Division of General Surgery
- 羅喬 Division of General Surgery
- YEN-SHEN LU Division of Hematology & Oncology
- MING-YANG WANG Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Tsu-Yi Chao Division of Hematology & Oncology
- 張平穎 Division of Hematology & Oncology
- 許桓銘 Division of General Surgery
- 戴明燊 Division of Hematology & Oncology
- 高偉堯 Division of Hematology & Oncology
- TSU-YI CHAO Division of Hematology & Oncology
- 何景良 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Fu Ouyang Division of General Surgery
- Fang-Ming Chen Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Huey-En Tzeng Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
64 participants
-
Global
3806 participants
